255 related articles for article (PubMed ID: 29609878)
1. A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.
Bennett RP; Salter JD; Smith HC
Trends Mol Med; 2018 May; 24(5):507-520. PubMed ID: 29609878
[TBL] [Abstract][Full Text] [Related]
2. Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors.
Binning JM; Smith AM; Hultquist JF; Craik CS; Caretta Cartozo N; Campbell MG; Burton L; La Greca F; McGregor MJ; Ta HM; Bartholomeeusen K; Peterlin BM; Krogan NJ; Sevillano N; Cheng Y; Gross JD
PLoS Pathog; 2018 Jan; 14(1):e1006830. PubMed ID: 29304101
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibition of HIV-1 Vif.
Nathans R; Cao H; Sharova N; Ali A; Sharkey M; Stranska R; Stevenson M; Rana TM
Nat Biotechnol; 2008 Oct; 26(10):1187-92. PubMed ID: 18806783
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
5. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
Baig TT; Feng Y; Chelico L
J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
[TBL] [Abstract][Full Text] [Related]
6. CBFß and HIV Infection.
Kim DY; Gross JD
Adv Exp Med Biol; 2017; 962():415-431. PubMed ID: 28299671
[TBL] [Abstract][Full Text] [Related]
7. Enhancing immunity to HIV through APOBEC.
Harris RS
Nat Biotechnol; 2008 Oct; 26(10):1089-90. PubMed ID: 18846074
[No Abstract] [Full Text] [Related]
8. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
[TBL] [Abstract][Full Text] [Related]
9. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.
Münk C; Jensen BE; Zielonka J; Häussinger D; Kamp C
Viruses; 2012 Nov; 4(11):3132-61. PubMed ID: 23202519
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vif, APOBEC, and intrinsic immunity.
Goila-Gaur R; Strebel K
Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
[TBL] [Abstract][Full Text] [Related]
12. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
13. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
14. Interaction between HIV-1 and APOBEC3 sub-family of proteins.
Arriaga ME; Carr J; Li P; Wang B; Saksena NK
Curr HIV Res; 2006 Oct; 4(4):401-9. PubMed ID: 17073615
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.
Cadima-Couto I; Saraiva N; Santos AC; Goncalves J
J Neuroimmune Pharmacol; 2011 Jun; 6(2):296-307. PubMed ID: 21279453
[TBL] [Abstract][Full Text] [Related]
16. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
18. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
Smith JL; Bu W; Burdick RC; Pathak VK
Trends Pharmacol Sci; 2009 Dec; 30(12):638-46. PubMed ID: 19837465
[TBL] [Abstract][Full Text] [Related]
19. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.
Smith JL; Pathak VK
J Virol; 2010 Dec; 84(24):12599-608. PubMed ID: 20943965
[TBL] [Abstract][Full Text] [Related]
20. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
